Company news: Lupin

| Updated on September 13, 2019 Published on September 13, 2019

Lupin has received approval for its propranolol hydrochloride extended-release (ER) capsules, 60 mg, 80 mg, 120 mg and 160 mg from Health Canada. Lupin is the first generic company to receive an approval for generic Inderal-LA capsules for the Canadian market and the product has been approved and will be manufactured from Lupin’s Pithampur Unit-2 facility. The medicine is for the treatment of hypertension and for the prophylaxis of angina pectoris. Shares of Lupin closed 0.64 per cent higher at ₹764 on the BSE.

Published on September 13, 2019
This article is closed for comments.
Please Email the Editor